Home » Ipsen Grants License to Debiopharm to Develop Proprietary CDC-251 Inhibitor
Ipsen Grants License to Debiopharm to Develop Proprietary CDC-251 Inhibitor
Pharmaceutical company Ipsen Promesses said Swiss-based Debiopharm Group has been granted an exclusive worldwide license to develop and commercialize its first-in-class inhibitor of the CDC25 phosphatase enzyme, now Debio 0931, for treating various human cancers.
RTTNews
RTTNews
Upcoming Events
-
07May
-
14May
-
30May